UNSPSC 85501625: Supplement left internal mammary artery with nonautologous tissue substitute, open approach

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement left internal mammary artery with nonautologous tissue substitute, open approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 03U10KZ

The UNSPSC Commodity code 85501625, Supplement left internal mammary artery with nonautologous tissue substitute, open approach, shows limited alignment with recent state and local procurement activity. The code nominally describes a specific surgical procedure, but recent opportunities posted under it reflect no cardiac surgical implant procurement. Instead, the code appears to be misapplied to a mix of health professional services, benefit administration, and occupational health programs that fall outside the code's surgical scope. The issuing bodies include city retirement offices, county health systems, state transportation departments, and county probation agencies—diverse public entities sourcing healthcare administration and staffing rather than surgical implants or tissue substitutes.

Geographic activity is scattered across Arizona, California, Florida, and Washington, with no concentration pattern evident. Representative recent solicitations include the City of Phoenix Retirement Office's request for independent medical evaluation services (RFP RTMRFP26001, due October 16, 2026), the City of Long Beach's surgical benefit carve-out program for employees (RFP HR26753, due October 7, 2026), and the Washington State Department of Transportation's occupational medical surveillance services (RFP RFP20260825, due October 9, 2026). The mismatch between the code's nominal definition and the actual work being procured signals either systematic misclassification in the source data or that this code is not currently used meaningfully for surgical implant procurement in state and local markets. No recent opportunities reflect the purchase of left internal mammary artery supplements or comparable cardiac surgical devices.